Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance

BSAC Resistance Surveillance Standing Committee, Michel Doumith, Shazad Mushtaq, Veronique Martin, Aiysha Chaudhry, Rachael Adkin, Juliana Coehlo, Vicki Chalker, Alasdair MacGowan, Neil Woodford, David M Livermore

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
7 Downloads (Pure)


Background: Like other streptococci, Streptococcus agalactiae typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in 2 of 1125 isolates collected in the BSAC Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterized. Methods: Identifications were by latex agglutination, MICs by BSAC agar dilution and sequencing by Illumina methodology. Results: Gentamicin MICs were >1024 mg/L versus a species mode of 8 mg/L; both isolates also were unusually ciprofloxacin resistant with MICs of 64 mg/L versus a species mode of 1 mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs globally. Both had aac(6′)-aph(2″), carried by different transposons, explaining their gentamicin resistance, and had gyrA[81:S-L];parC[79:S-Y], accounting for ciprofloxacin resistance. Conclusions: These are the first multiresistant S. agalactiae with the bifunctional AAC(6′)-APH(2″) enzyme to be reported in the UK for >10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin/gentamicin synergy is likely to be lost.
Original languageEnglish
Pages (from-to)2704–2707
JournalJournal of Antimicrobial Chemotherapy
Issue number10
Early online date6 Jul 2017
Publication statusPublished - 1 Oct 2017

Cite this